

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00455)**

**VOLUNTARY ANNOUNCEMENT  
INCREASE IN SHAREHOLDING BY  
THE CHAIRMAN AND MANAGING DIRECTOR**

This announcement is made voluntarily by Tianda Pharmaceuticals Limited (the “Company”) to keep the shareholders and potential investors of the Company informed of the latest information in relation to the increase in shareholding of the Company by Mr. Fang Wen Quan (“Mr. Fang”), the Chairman and Managing Director of the Company.

During the period from 19 October 2022 to 24 October 2022, Mr. Fang acquired a total of 1,930,000 Shares on the market, through his controlled entity Tianda Group Limited. Immediately after the increase in shareholding, Mr. Fang was interested in an aggregate of 1,196,901,370 Shares, representing approximately 55.67% of the issued share capital of the Company.

Mr. Fang is confident about the future prospects of the Company and may consider further increasing his shareholding in the Company when appropriate in the future, subject to compliance with the applicable legal and regulatory requirements.

*By order of the Board*  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 28 October 2022

*As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. SHEN Bo and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.*